Best Peptides for Beauty

The four most-researched beauty peptides available to South African researchers in 2026 are GHK-Cu, glutathione, Melanotan II, and Epithalon. Each has a distinct mechanism, a different evidence base, and a specific regulatory status under SAHPRA (South African Health Products Regulatory Authority).

By the end of this article, you will understand the mechanism and evidence strength for each peptide, the regulatory status in South Africa, and how to distinguish marketing claims from peer-reviewed findings.

The best peptides for beauty research in South Africa (2026) include:

• GHK-Cu, copper-binding tripeptide with collagen-synthesis and wound-repair data from fibroblast studies and small cosmetic trials
• Glutathione, antioxidant tripeptide studied for hyperpigmentation; oral dosing at 250–500 mg/day raises plasma levels over 6–12 weeks
• Melanotan II, synthetic melanocortin peptide; no active phase II/III trials as of 2026, flagged by SAHPRA as unregistered
• Epithalon, tetrapeptide bioregulator; human evidence limited to small Russian studies from the 1990s–2000s, with no modern replication

None of these compounds are SAHPRA-registered for cosmetic or beauty indications. Injectable and intravenous forms fall under the Medicines and Related Substances Act and require authorisation before use.

Why Peptides Matter for Beauty Research

Peptides are short chains of 2–50 amino acids that act as biological signals, making them some of the most precisely targeted molecules studied in cosmetic and skin-health research.

Unlike large proteins, peptides are small enough to penetrate the stratum corneum (the outermost layer of skin), specific enough to trigger defined cellular responses, and structurally simple enough to carry a lower immunogenicity risk than full-length biologicals. These properties explain why cosmetic peptide research accelerated sharply after 2015, as solid-phase synthesis costs dropped and formulators could produce research-grade sequences at scale. A 2024 cosmetic chemistry review noted that the global cosmetic peptide market had expanded significantly through the early 2020s, driven by consumer demand for actives with identifiable mechanisms rather than broad-spectrum botanical extracts.

The four peptides covered in this guide interact with skin biology through distinct pathways: copper-mediated collagen signalling, antioxidant enzyme modulation, melanocortin receptor activation, and telomerase-related gene expression. That specificity is what makes them subjects of ongoing research. For a broader look at how these compounds fit into skin-targeted applications, the best peptides for skin guide covers the skin-health angle in more detail, while readers interested in Epithalon's longevity context can refer to the best peptides for longevity overview.

One point applies to every compound on this page without exception: none are registered by SAHPRA for cosmetic or beauty use, and injectable or intravenous forms fall under the Medicines and Related Substances Act, which requires authorisation before administration. The research discussed here reflects laboratory, preclinical, and small-scale human study data, not approved therapeutic or cosmetic protocols.

GHK-Cu: The Collagen-Synthesis Peptide

GHK-Cu is a naturally occurring copper-peptide complex (glycyl-L-histidyl-L-lysine bound to a copper (II) ion) that upregulates collagen I, III, and IV synthesis in dermal fibroblasts, making it one of the most studied peptides in anti-ageing cosmetic formulations.

Key properties at a glance:

• Stimulates type I and type III collagen gene expression in fibroblast cell cultures at concentrations as low as 10⁻⁷–10⁻⁹ M
• Increases glycosaminoglycan production, supporting dermal hydration and structural integrity
• Studied for wound-healing acceleration and skin-barrier repair in preclinical models
• Commonly incorporated into topical serums and aesthetic clinic protocols in South Africa, where it is sold as a cosmetic ingredient rather than a registered medicine
• Human clinical data remains limited; the most-cited facial study involved 71 women over 12 weeks and reported increased skin density and reduced wrinkle depth, but was conducted pre-2020

The collagen claims rest on strong laboratory data but lack the large randomised controlled trials that modern evidence standards require.

What the Mechanism Actually Involves

GHK-Cu binds to cell-surface receptors and activates signalling cascades that switch on collagen-synthesis genes. A 2022 narrative review on GHK as an anti-ageing peptide confirmed this mechanism across multiple preclinical datasets but did not introduce new human collagen-synthesis trials. The copper component is not incidental: it acts as a cofactor for lysyl oxidase, the enzyme that cross-links newly synthesised collagen fibres into stable dermal matrix. Without functional copper binding, the peptide's collagen-promoting activity drops substantially.

A 2023 formulation study published in the Journal of Molecular Liquids developed an ionic-liquid microemulsion system for GHK-Cu and confirmed that the compound remains chemically stable and skin-permeable in that delivery format. This is a meaningful finding for topical formulators, though the study did not measure in-vivo collagen outcomes directly.

Where the Evidence Stands in 2026

GHK-Cu's collagen claims rest on strong but older laboratory data and small pre-2020 cosmetic trials, not large randomised controlled trials. No new large human study measuring dermal collagen directly has been published between 2020 and 2026. For researchers and formulators in South Africa, this means GHK-Cu is well-supported at the mechanistic level but lacks the clinical trial depth that would satisfy a modern evidence-grading framework.

Topical GHK-Cu products are widely available through South African aesthetic clinics and online retailers and are regulated as cosmetics provided they carry no therapeutic claims. Injectable forms fall under the Medicines and Related Substances Act and are not SAHPRA-registered for any beauty indication. Readers exploring the broader category of skin-targeted peptides can find additional context in the best peptides for skin guide.

Glutathione: The Antioxidant Peptide

Glutathione is a tripeptide (γ-glutamyl-cysteinyl-glycine) that is the body's primary intracellular antioxidant, neutralising free radicals and reactive oxygen species in skin cells while also modulating melanin synthesis in melanocytes.

Key facts about glutathione and skin health:

• Glutathione inhibits tyrosinase, the rate-limiting enzyme in melanin production, shifting pigment synthesis from darker eumelanin toward lighter phaeomelanin. This mechanism was confirmed in melanocyte studies cited in 2023 cosmetic dermatology research.
• Oral reduced glutathione has modest systemic bioavailability. A 2015 double-blind randomised controlled trial (RCT) showed roughly 30–35% increases in blood glutathione after 6–12 weeks of daily supplementation (250–500 mg/day), and 2024 pharmacokinetic reviews affirm this pattern while noting significant individual variability due to first-pass metabolism.
• IV glutathione achieves near-100% systemic availability and is used in hospital settings, but SAHPRA has issued repeated alerts (2020–2025) classifying cosmetic IV glutathione for skin lightening as an unregistered medicine, making it both legally problematic and potentially unsafe outside a clinical context.
• Topical glutathione acts primarily in the epidermis with minimal systemic absorption. Studies from 2023–2025 report improvements in hyperpigmentation and skin tone when glutathione is combined with other actives, making topical use better suited to localised brightening goals than to systemic antioxidant strategies.
• Glutathione participates in NAD+ metabolism and mitochondrial redox balance, which connects it to broader cellular energy research explored further in the best peptides for longevity guide.

Oral glutathione shows modest plasma increases, and IV use carries legal and safety risks that most marketing material ignores.

What the Research Actually Supports

Glutathione is a legitimate antioxidant with a plausible mechanism for skin brightening, but the route of administration matters enormously. Topical preparations are the most accessible and legally straightforward option for South African consumers, with evidence supporting localised pigmentation effects. Oral supplementation can raise plasma glutathione over weeks of consistent use, though the effect size is moderate. IV administration delivers the strongest exposure but sits firmly in regulated medical territory under the Medicines and Related Substances Act, and no IV glutathione product is SAHPRA-registered for any cosmetic indication.

Researchers interested in skin-targeted peptide applications more broadly will find relevant mechanistic context in the best peptides for skin guide.

Melanotan II: Melanogenesis and Tanning Research

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (primarily MC1R and MC4R) to stimulate eumelanin production in melanocytes, producing a darkening of the skin without UV exposure.

Reported side effects associated with Melanotan II use include:

• Nausea and facial flushing, documented consistently across user reports and case series from 2023 to 2025
• Spontaneous erections, a consequence of MC4R activation observed in pre-2010 phase I/II trials and still frequently reported
• Rapid darkening or new appearance of melanocytic nevi and atypical pigmented lesions, with some cases prompting biopsy; temporal association with melanoma has been noted, though causality is unproven
• Injection-site infections and abscesses linked to non-sterile, internet-sourced vials manufactured outside GMP (Good Manufacturing Practice) controls
• Transient increases in blood pressure and heart rate, flagged in pharmacovigilance summaries from 2023 to 2025

Melanotan II carries documented safety signals, including pigmented lesion changes, and no modern clinical development is underway to address them.

Research Status as of 2026

No phase II or III clinical trials of Melanotan II are actively progressing to publication as of 2026. The formal human evidence base dates almost entirely to pre-2010 studies, which confirmed MC1R/MC4R-mediated pigmentation and erectile responses but did not translate into any approved therapeutic indication. Current dermatology and toxicology literature from 2024 to 2026 focuses on safety concerns rather than new efficacy data.

Melanotan II is not approved by SAHPRA, the FDA (Food and Drug Administration), or the EMA (European Medicines Agency) for any cosmetic or therapeutic use. SAHPRA has issued repeated safety alerts between 2020 and 2025 classifying unregistered tanning peptides as illegal and potentially harmful under the Medicines and Related Substances Act. Products sold online as "research use only" remain unregistered and carry the same legal and safety risks as any unlicensed injectable medicine.

What the Research Actually Supports

The mechanism is pharmacologically plausible and the pigmentation effect is real, but the risk profile is poorly characterised for long-term use. Any sudden mole changes, new dark lesions, or systemic symptoms following Melanotan II use warrant urgent dermatological review. Researchers exploring skin-targeted peptides with a more established safety record will find the best peptides for skin guide covers compounds with broader human data.

Epithalon: The Telomerase-Pathway Peptide

Epithalon (also written Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, developed from a natural pineal gland extract called Epithalamin. Its proposed mechanism centres on upregulating telomerase activity in somatic cells, which theoretically slows telomere shortening and reduces markers of cellular senescence.

Epithalon's human evidence base is narrow, geographically isolated, and has not been independently replicated in modern trials.

What the Research Actually Shows

The foundational clinical work comes from a St. Petersburg gerontology group whose trials in elderly cohorts during the 1990s and 2000s reported improvements in melatonin secretion, immune parameters, and observational signals for reduced mortality when Epithalon was combined with other peptide bioregulators. Those studies fall short of modern randomised controlled trial standards in blinding, sample size, and independent replication.

A wave of interest in longevity research between 2020 and 2023 produced case series and practitioner reports from anti-ageing clinics, but none of these are indexed as rigorous trials. Searches of major clinical trial registries as of 2025–2026 return no active late-phase Epithalon anti-ageing trials. No new peer-reviewed, placebo-controlled human study measuring telomerase activity or lifespan outcomes has been published in a major journal between 2020 and 2026.

The telomerase-activation mechanism is biologically plausible. Telomerase does decline with age, and peptide bioregulators have shown activity in cell culture and animal models. The gap between that preclinical signal and confirmed human benefit remains wide and unresolved.

Key Evidence Gaps at a Glance

• Human trials to date are small, conducted by a single research group, and have not been independently replicated in Western or large multinational studies
• No active phase II or III clinical trials appear in registry searches as of 2026
• Claims about lifespan extension rest on animal data and theoretical telomerase mechanisms, not controlled human outcomes
• SAHPRA has not registered Epithalon for any cosmetic or therapeutic indication; injectable forms sold online are unregistered under the Medicines and Related Substances Act

Regulatory and Availability Context in South Africa

SAHPRA classifies injectable or systemic peptides as medicines requiring registration, and Epithalon holds no such registration in South Africa as of 2026. Products marketed online as "research use only" carry the same legal and safety risks as any other unlicensed injectable medicine. Researchers with a genuine interest in telomere biology and cellular ageing will find broader context in the best peptides for longevity guide. For skin-specific applications where the evidence base is stronger, the best peptides for skin guide is a more grounded starting point.

Comparison: Mechanism, Evidence, and Research Status 2026

The four compounds span a wide range, from reasonably well-documented topical effects to almost entirely preclinical claims. The table below maps each peptide against its primary mechanism, the strongest evidence type available, and its current trial status as of 2026.

Peptide	Primary Mechanism	Target Pathway	Strongest Evidence Type	Active Human Trials (2026)
GHK-Cu	Stimulates collagen and glycosaminoglycan synthesis	Fibroblast activation, TGF-β signalling	In vitro fibroblast data + small older human cosmetic trials	None identified
Glutathione	Antioxidant; inhibits tyrosinase to reduce melanin	Oxidative stress reduction, melanogenesis	Oral RCT data (modest plasma increases); topical hyperpigmentation studies	Limited; no large registered trials
Melanotan II	Activates MC1R/MC4R receptors to drive melanin production	Melanocortin receptor signalling	Phase I/II human data pre-2010; current literature is safety-focused	None registered
Epithalon	Proposed telomerase activation to extend telomere length	Telomere biology, cellular senescence	Animal models + small Russian cohort studies from the 1990s–2000s	None registered

What the Evidence Gaps Mean in Practice

GHK-Cu is the most evidence-supported compound for topical skin applications, though the human trial data is older and no large randomised controlled trials have been completed since 2020. Glutathione sits in the middle: oral supplementation has demonstrated measurable plasma increases in controlled trials, and topical formulations show localised pigmentation benefits in 2023–2025 dermatology studies, but systemic cosmetic claims outpace the evidence.

Melanotan II and Epithalon share a common problem. The human data that exists is either pre-2010, methodologically limited, or geographically narrow, and neither compound has active late-phase trials progressing toward regulatory approval anywhere in the world. SAHPRA has not registered any of these four compounds for cosmetic or therapeutic use in injectable or systemic form.

Researchers wanting deeper context on skin-specific peptide applications can refer to the best peptides for skin guide, while those focused on cellular ageing mechanisms will find broader discussion in the best peptides for longevity guide.

Quick-Reference Evidence Summary

• GHK-Cu, strongest topical evidence of the four; collagen data is real but rests on older in vitro and small human studies
• Glutathione, oral and topical routes have the most recent human data; IV use is unregistered and flagged by SAHPRA
• Melanotan II, no active clinical development; current research focus is safety signals, not efficacy
• Epithalon, no modern independent replication; human evidence base has not materially advanced since the early 2000s

South African Regulatory and Sourcing Context

None of the four peptides covered in this guide (GHK-Cu, glutathione in injectable or systemic form, Melanotan II, and Epithalon) are registered by SAHPRA for cosmetic or therapeutic use in South Africa.

What SAHPRA's Position Means in Practice

SAHPRA classifies any product delivered by injection, or any product making therapeutic claims such as skin-lightening or anti-ageing, as a medicine under the Medicines and Related Substances Act. Registration is required regardless of how the product is labelled. "Research use only" or "cosmetic" marketing does not exempt a compound from this requirement. SAHPRA has issued repeated safety alerts between 2020 and 2025 specifically naming Melanotan II tanning peptides and unregistered IV glutathione as illegal and potentially harmful.

Topical cosmetics containing low-dose GHK-Cu occupy a narrower grey area. Provided they carry no therapeutic claims, they are generally assessed under cosmetic product standards rather than medicines legislation, which is why GHK-Cu serums are sold openly through retail and aesthetic clinics.

Sourcing for Research Purposes

For researchers working within a laboratory context, sourcing from a reputable South African supplier such as Body Pharm is the practical starting point. Established research suppliers provide certificates of analysis, documented purity testing, and batch traceability, none of which are guaranteed when ordering from unverified international websites.

Importing peptides for personal use carries compounded risk: customs interception, unknown purity, non-sterile manufacturing conditions, and potential legal liability. Regulatory and poison-centre bulletins from 2023 to 2025 confirm that grey-market vials frequently show batch-to-batch variability and undisclosed adulterants.

Researchers interested in skin-targeted applications can find compound-specific sourcing considerations in the best peptides for skin guide, and those examining Epithalon within a broader cellular ageing framework will find relevant context in the best peptides for longevity guide.

The single most reliable rule for South African researchers in 2026: if a peptide is not SAHPRA-registered and is intended for injection or systemic use, it is legally unregistered and must be treated accordingly, regardless of what the supplier's website states.

What the Research Actually Shows vs. Marketing Claims

The gap between peptide marketing and peer-reviewed evidence is wide, and understanding it is the most practical thing a South African researcher or consumer can do before spending money or assuming risk.

GHK-Cu: Strong Lab Data, Thin Human Trial Record

GHK-Cu is the best-evidenced peptide on this list for skin applications, but that evidence has a ceiling. In vitro fibroblast studies consistently show that GHK-Cu at concentrations of 10⁻⁷–10⁻⁹ M increases type I and III collagen synthesis and glycosaminoglycan production. A facial study on 71 women reported increased skin density and reduced wrinkles over 12 weeks of topical application. Those findings are real, but they date from the 1990s to early 2000s, and as of 2026, no large randomised controlled trial has replicated or extended them. A 2022 narrative review summarised the same pre-existing data without adding new collagen-synthesis trials. "Studied for collagen production" is not the same as "proven to produce collagen in humans at scale."

Glutathione: Antioxidant Mechanism Is Sound, Delivery Is the Problem

Glutathione's role as a cellular antioxidant is not disputed. The delivery question is where marketing diverges from pharmacokinetics. Oral supplementation at 250–500 mg per day raises plasma glutathione levels by roughly 30–35% over six to twelve weeks, according to controlled trial data summarised in 2024 pharmacology reviews. That is a modest, real effect. Topical glutathione acts locally in the epidermis and shows improvements in hyperpigmentation in 2023–2025 cosmetic dermatology studies, but systemic absorption is minimal. IV administration achieves near-100% bioavailability but is flagged by SAHPRA as unregistered for cosmetic use and carries documented safety risks. Route of administration matters enormously, and most marketing ignores it entirely.

Melanotan II: Mechanistically Active, Clinically Abandoned

Melanotan II does stimulate melanin production via MC1R and MC4R receptor activation. That mechanism is not in question. What is in question is whether any responsible clinical programme is still pursuing it. As of 2026, no phase II or III trials are progressing toward publication, and current dermatology literature from 2024 focuses on safety signals: rapid darkening of melanocytic nevi, atypical pigmented lesions requiring biopsy, nausea, flushing, and injection-site infections from non-sterile vials. Preclinical efficacy and human safety are separate questions, and Melanotan II has not resolved the second one.

Epithalon: Theoretical Promise, No Modern Human Evidence

Epithalon is frequently marketed on the basis of telomerase activation and cellular longevity, but the human evidence base does not support confident claims. All available human data come from small Russian studies conducted in the 1990s and 2000s, reporting improvements in melatonin secretion and immune parameters in elderly cohorts. Those studies fall short of modern RCT standards, and as of 2026, no late-phase Epithalon trial appears in major clinical trial registries. Practitioner case series from longevity clinics circulating since 2020 are uncontrolled and not peer-reviewed. Researchers exploring Epithalon within a broader cellular ageing framework will find relevant context in the best peptides for longevity guide.

The consistent pattern across all four compounds is that cell-culture results and early-phase signals get amplified into product claims long before human trials confirm them. For anyone assessing skin-specific applications, the best peptides for skin guide applies the same evidence standard to formulation and delivery questions.

How to Evaluate Peptide Research Quality

Not all peptide studies carry equal weight, and the gap between a cell-culture result and a confirmed human outcome is wider than most product pages suggest.

The Evidence Hierarchy Matters

In vitro studies (experiments on isolated cells in a dish) are the easiest to conduct and publish, but they are the least predictive of what happens in living human skin. A fibroblast culture responding to GHK-Cu at 10⁻⁷ M tells you the mechanism is plausible; it does not confirm that a topical serum delivers that concentration to the dermis of a 50-year-old. Animal studies add biological complexity but still involve different skin architecture, metabolism, and immune responses. Human randomised controlled trials (RCTs) are the gold standard, and for peptides they remain rare.

What to Check Before Trusting a Study

When you encounter a peptide study cited in marketing material, four questions cut through most of the noise:

• Who funded it? Supplier-funded studies without independent replication deserve scepticism. A 2022 narrative review on GHK summarised decades of preclinical and early human data but added no new collagen-synthesis trials of its own.
• When was it published? Epithalon's entire human dataset originates from Russian studies conducted in the 1990s and 2000s, with no modern peer-reviewed replication. Age alone does not invalidate a study, but stale data without replication is a red flag.
• What was the study population? A 12-week facial trial on 71 middle-aged women is more informative than a case series from a longevity clinic, but it is still far smaller than the RCTs regulators require for drug approval.
• Was it peer-reviewed and indexed? Practitioner reports circulating in anti-ageing communities since 2020 are largely uncontrolled and not indexed in major databases.

Supplier Claims vs. Independent Science

Peptide suppliers frequently cite in vitro fibroblast data as though it confirms topical efficacy in humans. The translation rate from cell culture to clinical outcome is low across pharmacology generally, and peptide delivery through intact skin adds another barrier. Readers exploring skin-specific formulation questions will find the best peptides for skin guide applies this same evidence standard to absorption and delivery. For compounds like Epithalon, where longevity claims extend beyond cosmetics, the best peptides for longevity guide contextualises the same thin evidence base within cellular ageing research.

Safety, Side Effects, and What We Don't Know

None of the four peptides covered here carry SAHPRA or FDA approval for human use, which means formal post-market safety surveillance simply does not exist for them.

GHK-Cu

Topical GHK-Cu has a long cosmetic track record with no serious adverse events documented in the small human trials conducted through the 2000s. The safety gap is systemic: injectable or high-dose formulations have not been studied in adequately powered human trials, so tolerability beyond the skin surface remains uncharacterised.

Glutathione

Oral glutathione at 250–500 mg per day raised plasma levels by roughly 30–35% in a controlled trial without notable adverse events, though individual variability is significant. IV glutathione is a different matter. Administered outside a clinical setting, it carries real risks of injection-site infection, phlebitis, and contamination from unsterile preparation. SAHPRA has issued repeated alerts between 2020 and 2025 flagging unregistered IV glutathione for skin lightening as both illegal and potentially harmful.

Melanotan II

Melanotan II carries the most documented safety concerns of the four. Dermatology case reports from 2023 to 2025 consistently describe nausea, facial flushing, spontaneous erections, decreased appetite, and systemic malaise even at self-administered doses. More seriously, multiple case reports from the same period document rapid darkening of existing moles and the appearance of new atypical pigmented lesions following use, with some prompting biopsy. Causality between Melanotan II and melanoma has not been proven, but dermatologists advise that any sudden mole changes after use warrant urgent review. Injection-site abscesses and contamination from non-sterile, internet-sourced vials add further risk. Long-term safety data do not exist; the last structured human trials were conducted before 2010.

Epithalon

Human safety data for Epithalon are minimal. The available evidence comes from small Russian cohort studies conducted in the 1990s and 2000s, which reported no major adverse events but were not designed or powered to detect rare harms. No modern placebo-controlled trial has assessed its safety profile, and clinical trial registries show no active late-phase studies as of 2026.

Researchers exploring skin-specific tolerability questions will find the best peptides for skin guide addresses delivery and absorption risks in more detail. For Epithalon's broader unknowns within cellular ageing research, the best peptides for longevity guide applies the same evidence standard.

Where to Source Beauty Peptides in South Africa

Sourcing from a verified research supplier is the single most important quality decision you will make. SAHPRA has issued repeated alerts between 2020 and 2025 warning that unregistered injectable peptides, including Melanotan II and IV glutathione, are circulating through unregulated online channels with no quality controls. Products from these sources carry unknown purity, uncertain dosing, and contamination risks that documented case reports have already linked to injection-site abscesses.

What a Reputable Supplier Looks Like

Established research suppliers provide a certificate of analysis (CoA) for every batch, showing purity of 95% or above confirmed by high-performance liquid chromatography (HPLC) and mass spectrometry. Body Pharm is an example of a South African supplier that publishes third-party testing documentation and labels products clearly as research use only, not for human consumption. That labelling is not a legal formality; it reflects the actual SAHPRA registration status of these compounds.

Red Flags to Avoid

• No CoA available, or a CoA that cannot be traced to an independent laboratory
• Pricing significantly below market rate (R200–R300 for a 10 mg vial of GHK-Cu, for instance, should prompt questions about testing costs)
• Supplier websites making therapeutic claims such as "treats wrinkles" or "lightens skin", which signal non-compliance with the Medicines and Related Substances Act
• No physical South African address or contact number

Price variation in the peptide market almost always reflects testing standards. A supplier absorbing the cost of third-party HPLC verification will price accordingly. Researchers interested in skin-specific delivery considerations can find additional sourcing context in the best peptides for skin guide, and those focused on Epithalon within a broader anti-ageing programme will find relevant supplier notes in the best peptides for longevity guide.

Key Takeaways: Beauty Peptides in 2026

The four peptides covered in this guide sit at very different points on the evidence spectrum, and none has cleared the bar of large, placebo-controlled human trials for cosmetic use.

• GHK-Cu has the strongest topical evidence base: fibroblast studies confirm collagen and glycosaminoglycan stimulation, and small human trials from the 1990s–2000s showed measurable skin-density improvements over 12 weeks, though no large RCTs have been published since.
• Glutathione shows modest but real systemic effects with oral dosing (roughly 30–35% plasma increases after 6–12 weeks in controlled trials), while topical formulations target localised hyperpigmentation rather than whole-body antioxidant status.
• Melanotan II has no active mainstream clinical development as of 2026; current literature focuses on safety signals, including pigmented lesion changes and systemic side effects, rather than new efficacy data.
• Epithalon's human evidence comes almost entirely from small Russian cohort studies conducted before 2010, with no modern placebo-controlled replication published in major journals.

"Studied for" is not the same as "proven effective in humans." Source from a supplier that provides third-party HPLC documentation, understand that all four are unregistered under SAHPRA for cosmetic or therapeutic indications, and speak with a dermatologist before proceeding.

Next Steps

Start by identifying your specific research goal: skin-targeted applications, cellular ageing mechanisms, or hyperpigmentation. Researchers focused on skin applications can find additional context in the best peptides for skin guide; those interested in Epithalon within a longevity programme should consult the best peptides for longevity guide. Once you have narrowed your focus, contact a South African supplier with published third-party testing documentation and request their certificate of analysis for the specific batch you are considering. Finally, consult a dermatologist or clinical researcher familiar with peptide pharmacology before proceeding with any compound.